keyword
MENU ▼
Read by QxMD icon Read
search

HER2 positive

keyword
https://www.readbyqxmd.com/read/28723928/erbb-activation-signatures-as-potential-biomarkers-for-anti-erbb3-treatment-in-hnscc
#1
Diego Alvarado, Gwenda F Ligon, Jay S Lillquist, Scott B Seibel, Gerald Wallweber, Veronique M Neumeister, David L Rimm, Gerald McMahon, Theresa M LaVallee
Head and neck squamous cell carcinoma (HNSCC) accounts for 3-5% of all tumor types and remains an unmet medical need with only two targeted therapies approved to date. ErbB3 (HER3), the kinase-impaired member of the EGFR/ErbB family, has been implicated as a disease driver in a number of solid tumors, including a subset of HNSCC. Here we show that the molecular components required for ErbB3 activation, including its ligand neuregulin-1 (NRG1), are highly prevalent in HNSCC and that HER2, but not EGFR, is the major activating ErbB3 kinase partner...
2017: PloS One
https://www.readbyqxmd.com/read/28723628/ese-1-elf3-mrna-expression-associates-with-poor-survival-outcomes-in-her2-breast-cancer-patients-and-is-critical-for-tumorigenesis-in-her2-breast-cancer-cells
#2
Adwitiya Kar, Arthur Gutierrez-Hartmann
ESE-1/Elf3 and HER2 appear to establish a positive feedback regulatory loop, but the precise role of ESE-1 in HER2+ breast tumorigenesis remains unknown. Analyzing public repositories, we found that luminal B and HER2 subtype patients with high ESE-1 mRNA levels displayed worse relapse free survival. We stably knocked down ESE-1 in HER2+ luminal B BT474 cells and HER2 subtype SKBR3 cells, which resulted in decreased cell proliferation, colony formation, and anchorage-independent growth in vitro. Stable ESE-1 knockdown inhibited HER2-dependent signaling in BT474 cells and inhibited mTOR activation in SKBR3 cells, but reduced Akt signaling in both cell types...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28721185/the-smooth-and-bumpy-road-of-trastuzumab-administration-from-intravenous-iv-in-a-hospital-to-subcutaneous-sc-at-home
#3
Waa Tjalma, M T Huizing, K Papadimitriou
Trastuzumab has become standard of care in the treatment of early and metastatic HER2-positive breast cancer. Initially trastuzumab could only be administered intravenously (IV), however since a few years there is also a subcutaneous (SC) formulation. The efficacy and the safety profile of both formulations is the comparable. The administration logistics however have an impact on the patients, the health care professionals (HCPs), the hospital and the government. The preference for the patients (89%) and the HCPs (77%) is in favour of the SC formulation...
March 2017: Facts, Views & Vision in ObGyn
https://www.readbyqxmd.com/read/28718331/entinostat-for-the-treatment-of-breast-cancer
#4
Dario Trapani, Angela Esposito, Carmen Criscitiello, Luca Mazzarella, Marzia Locatelli, Ida Minchella, Saverio Minucci, Giuseppe Curigliano
Breast cancer accounts for 29% of malignant tumors. It is an heterogenous disease covering a spectrum of different molecular subtypes. Epigenetic aberrations may affect gene expression through DNA and histone proteins modifications thus promoting tumor progression and resistance to anti- tumor treatment. Area covered: This article explores the potential role of entinostat in the treatment of breast cancer. The clinical trials evaluating entinostat are discussed, highlighting preclinical data and early-phase clinical studies results...
July 18, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28717761/estimation-of-premature-deaths-from-lack-of-access-to-anti-her2-therapy-for-advanced-breast-cancer-in-the-brazilian-public-health-system
#5
Márcio Debiasi, Tomás Reinert, Rafael Kaliks, Gilberto Amorim, Maira Caleffi, Carlos Sampaio, Gustavo Dos Santos Fernandes, Carlos H Barrios
PURPOSE: Patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic tumors treated in the public health system in Brazil do not have access to trastuzumab. This study aimed to estimate the impact of the lack of access to anti-HER2 therapies on the mortality of these patients. METHODS: On the basis of published data, the number of patients with HER2-positive advanced breast cancer in 2016 who should receive anti-HER2 targeted therapy was estimated...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28713499/relationship-among-mammographic-findings-with-histopathologic-type-of-breast-cancer-and-human-epidermal-growth-factor-receptor-2-her2-in-young-women
#6
Donya Farrokh, Samineh Boloursaz, Fatemeh Homai
INTRODUCTION: Radiological measures to diagnose breast cancer, including mammographic and ultrasound assessments in young women, are associated with restrictions affecting the use of this tool. No adequate information is available on mammography view in young people with breast cancer and its relationship with pathologic type and epidermal growth factor receptor 2 (HER2) as a prognostic marker, especially in the Iranian race. This study was conducted to examine the relationship between mammographic findings of young women with breast cancer with diagnosed histopathologic type and HER2 marker status...
May 2017: Electronic Physician
https://www.readbyqxmd.com/read/28712009/analysis-of-molecular-subtypes-for-the-increased-her2-equivocal-cases-caused-by-application-of-the-updated-2013-asco-cap-her2-testing-guidelines-in-breast-cancer
#7
Lei Guo, Pei Yuan, Jing Zhang, Yun Ling, Wenbin Li, Bohui Zhao, Jianming Ying, Lixue Xuan
PURPOSE: Accurate testing of the status of human epidermal growth factor receptor type 2 (HER2) is a prerequisite for HER2-directed therapy. The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) published joint guideline recommendations for HER2 testing in breast cancer in 2007 and it was updated in 2013. We compared the HER2 gene amplification status based on these two guidelines and analyzed the molecular characteristics of the equivocal cases...
July 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28711994/-18-f-fdg-pet-ct-features-for-the-molecular-characterization-of-primary-breast-tumors
#8
Lidija Antunovic, Francesca Gallivanone, Martina Sollini, Andrea Sagona, Alessandra Invento, Giulia Manfrinato, Margarita Kirienko, Corrado Tinterri, Arturo Chiti, Isabella Castiglioni
PURPOSE: The aim of this study was to evaluate the role of imaging features derived from [(18)F]FDG-PET/CT to provide in vivo characterization of breast cancer (BC). METHODS: Images from 43 patients with a first diagnosis of BC were reviewed. Images were acquired before any treatment. Histological data were derived from pretreatment biopsy or surgical histological specimen; these included tumor type, grade, ER and PgR receptor status, lymphovascular invasion, Ki67 index, HER2 status, and molecular subtype...
July 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28711937/magnetic-resonance-metabolic-profiling-of-estrogen-receptor-positive-breast-cancer-correlation-with-currently-used-molecular-markers
#9
Ji Soo Choi, Dahye Yoon, Ja Seung Koo, Siwon Kim, Vivian Youngjean Park, Eun-Kyung Kim, Suhkmann Kim, Min Jung Kim
Estrogen receptor (ER)-positive breast cancers overall have a good prognosis, however, some patients suffer relapses and do not respond to endocrine therapy. The purpose of this study was to determine whether there are any correlations between high-resolution magic angle spinning (HR-MAS) magnetic resonance spectroscopy (MRS) metabolic profiles of core needle biopsy (CNB) specimens and the molecular markers currently used in patients with ER-positive breast cancers. The metabolic profiling of CNB samples from 62 ER-positive cancers was performed by HR-MAS MRS...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28711793/efficacy-and-safety-of-everolimus-and-exemestane-in-hormone-receptor-positive-hr-human-epidermal-growth-factor-negative-her2-advanced-breast-cancer-patients-new-insights-beyond-clinical-trials-the-eva-study
#10
M E Cazzaniga, M Airoldi, V Arcangeli, S Artale, F Atzori, A Ballerio, G V Bianchi, L Blasi, S Campidoglio, M Ciccarese, M C Cursano, M Piezzo, A Fabi, L Ferrari, A Ferzi, C Ficorella, A Frassoldati, A Fumagalli, O Garrone, V Gebbia, D Generali, N La Verde, M Maur, A Michelotti, G Moretti, A Musolino, R Palumbo, M Pistelli, M Porpiglia, D Sartori, C Scavelli, A Schirone, A Turletti, M R Valerio, P Vici, A Zambelli, L Clivio, V Torri
BACKGROUND: The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant...
July 13, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28710747/phase-i-study-of-chimeric-antigen-receptor-modified-t-cells-in-treating-her2-positive-advanced-biliary-tract-cancers-and-pancreatic-cancers
#11
Kaichao Feng, Yang Liu, Yelei Guo, Jingdan Qiu, Zhiqiang Wu, Hanren Dai, Qingming Yang, Yao Wang, Weidong Han
This phase I clinical trial (NCT01935843) is to evaluate the safety, feasibility, and activity of chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancers (BTCs) and pancreatic cancers (PCs). Eligible patients with HER2-positive (>50%) BTCs and PCs were enrolled in the trial. Well cultured CART-HER2 cells were infused following the conditioning treatment composed of nab-paclitaxel (100-200 mg/m(2)) and cyclophosphamide (15-35 mg/kg)...
July 14, 2017: Protein & Cell
https://www.readbyqxmd.com/read/28710537/cardiac-safety-of-non-anthracycline-trastuzumab-based-therapy-for-her2-positive-breast-cancer
#12
Anthony F Yu, Roy B Mukku, Shivani Verma, Jennifer E Liu, Kevin C Oeffinger, Richard M Steingart, Clifford A Hudis, Chau T Dang
PURPOSE: Trastuzumab improves overall survival for women with HER2-positive breast cancer but is associated with cardiotoxicity, especially when administered after anthracyclines. Use of non-anthracycline trastuzumab-based regimens is rising, particularly for patients with low-risk disease or with multiple cardiovascular risk factors. We performed a single-center retrospective cohort study to assess the cardiac safety of trastuzumab without anthracyclines outside of a clinical trial setting...
July 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28707744/the-impact-of-molecular-subtype-on-breast-cancer-recurrence-in-young-women-treated-with-contemporary-adjuvant-therapy
#13
Hanan Alabdulkareem, Tiffany Pinchinat, Sarah Khan, Alyssa Landers, Paul Christos, Rache Simmons, Tracy-Ann Moo
Breast cancer is the leading cause of cancer death in women younger than 40 years. Triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2) positive subtypes have a particularly poor prognosis in this age group. The purpose of this study was to compare rates of recurrence among breast cancer subtypes in young patients treated with modern adjuvant systemic therapy. A retrospective review of breast cancer patients managed at a major academic breast center between May 2000 and November 2014 was performed...
July 14, 2017: Breast Journal
https://www.readbyqxmd.com/read/28704710/dissecting-the-biological-heterogeneity-within-hormone-receptor-positive-her2-negative-breast-cancer-by-gene-expression-markers-identifies-indolent-tumors-within-late-stage-disease
#14
Jyothi S Prabhu, Aruna Korlimarla, C E Anupama, Annie Alexander, Rohini Raghavan, Roma Kaul, Krisha Desai, Savitha Rajarajan, Suraj Manjunath, Marjorrie Correa, R Raman, Anjali Kalamdani, Msn Prasad, Shekar Patil, K S Gopinath, B S Srinath, T S Sridhar
Hormone receptor positive (HR+) breast cancers are a heterogeneous class with differential prognosis. Although more than half of Indian women present with advanced disease, many such patients do well. We have attempted identification of biologically indolent tumors within HR+HER2- tumors based on gene expression using histological grade as a guide to tumor aggression. 144 HR+HER2- tumors were divided into subclasses based on scores derived by using transcript levels of multiple genes representing survival, proliferation, and apoptotic pathways and compared to classification by Ki-67 labeling index (LI)...
July 11, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28702894/21-gene-recurrence-score-and-locoregional-recurrence-in-lymph-node-negative-estrogen-receptor-positive-breast-cancer
#15
Gulisa Turashvili, Joanne F Chou, Edi Brogi, Monica Morrow, Maura Dickler, Larry Norton, Clifford Hudis, Hannah Y Wen
BACKGROUND/PURPOSE: The 21-gene recurrence score (RS) assay evaluates the likelihood of distant recurrence and benefit of chemotherapy in lymph node-negative, estrogen receptor (ER)-positive, HER2-negative breast cancer patients. The RS categories are associated with the risk of locoregional recurrence (LRR) in some, but not all studies. METHODS: We reviewed the institutional database to identify consecutive female patients with node-negative, ER+/HER2- breast carcinoma tested for the 21-gene RS assay and treated at our center from 2008 to 2013...
July 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28702892/a-small-molecule-inhibitor-of-smad3-attenuates-resistance-to-anti-her2-drugs-in-her2-positive-breast-cancer-cells
#16
Yoko Chihara, Masafumi Shimoda, Ami Hori, Ako Ohara, Yasuto Naoi, Jun-Ichiro Ikeda, Naofumi Kagara, Tomonori Tanei, Atsushi Shimomura, Kenzo Shimazu, Seung Jin Kim, Shinzaburo Noguchi
PURPOSE: Resistance against anti-HER2 drugs in HER2-positive breast cancer is a major obstacle to the improving prognosis. Transforming growth factor β (TGFβ) is a cytokine involved in the acquisition of more malignant phenotypes through epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) properties. The aim of this study was to investigate the effects of TGFβ and its downstream SMAD pathway on resistance to anti-HER2 drugs. METHODS: HER2-positive breast cancer cell lines were stimulated with TGFβ for 14 days...
July 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28702778/characterization-of-her2-gene-amplification-heterogeneity-in-invasive-and-in-situ-breast-cancer-using-bright-field-in-situ-hybridization
#17
António Polónia, Guilherme Oliveira, Fernando Schmitt
The aims of this study were to evaluate and compare the HER2 gene amplification status in invasive and adjacent in situ breast carcinoma, using bright-field in situ hybridization, and to document the possible presence of HER2 genetic heterogeneity (HER2-GH) in both components. A cohort of 100 primary invasive carcinomas (IC) associated with carcinoma in situ (CIS) were evaluated for HER2 gene amplification by SISH according to the 2013 ASCO/CAP HER2 guideline. A second cohort of all the cases with HER2-GH since the introduction of the updated ASCO/CAP HER2 guideline was also characterized, and an evaluation of the HER2 gene amplification in the CIS component, if present, was also done...
July 13, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28702403/efficacy-and-safety-of-short-course-adjuvant-trastuzumab-combination-chemotherapy-in-breast-cancer
#18
Sachin S Hingmire, Mahesh B Sambhus, Dhananjay S Kelkar, Sujit Joshi, Purvish M Parikh, R Bharath
BACKGROUND: The adjuvant short course 9-week trastuzumab combination therapy for human epidermal receptor 2 positive breast cancer patients may often be considered as a cost-effective and safe option and has important implications for the Indian subcontinent as well as other developing countries. However, such regimens of shorter duration trastuzumab therapy like FinHer, offered in view of economic constraints, may not be able to achieve globally comparable cure rates in early breast cancer especially with high-risk women with more than 3 lymph node positive...
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28702401/outcome-of-her2-testing-by-fish-applying-asco-cap-2007-and-2013-guideline-in-ihc-equivocal-group-of-breast-cancer-experience-at-tertiary-cancer-care-centre
#19
Manoj Kumar Panigrahi, Dushyant Kumar, Anurag Mehta, Kandarpa Kumar Saikia
BACKGROUND AND OBJECTIVES: HER2 testing guideline of ASCO/CAP for interpretation and reporting has recently been revised. The study is aimed to measure the impact of 2013 CAP guideline on equivocal HER2 test outcome (immunohistochemistry [IHC] 2+) when tested by fluorescent in situ hybridization (FISH). The study also aims at finding the frequency of polysomy and monosomy of chromosome 17. MATERIALS AND METHODS: Specimens were collected in Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India...
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28701571/neoadjuvant-therapy-with-weekly-nanoparticle-albumin-bound-paclitaxel-for-luminal-early-breast-cancer-patients-results-from-the-nabrax-study-geicam-2011-02-a-multicenter-non-randomized-phase-ii-trial-with-a-companion-biomarker-analysis
#20
Miguel Martín, José I Chacón, Antonio Antón, Arrate Plazaola, Elena García-Martínez, Miguel A Seguí, Pedro Sánchez-Rovira, José Palacios, Lourdes Calvo, Carmen Esteban, Enrique Espinosa, Agusti Barnadas, Norberto Batista, Angel Guerrero, Montserrat Muñoz, Estefania Romio, César Rodríguez-Martín, Rosalía Caballero, María I Casas, Federico Rojo, Eva Carrasco, Silvia Antolín
BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel) is an alternative to standard taxanes for breast cancer (BC) treatment. We evaluated nab-Paclitaxel efficacy as neoadjuvant treatment for early estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) disease. MATERIALS AND METHODS: Women with ER+, HER2-, stage II-III BC were treated preoperatively with four cycles of weekly nab-Paclitaxel (150 mg/m(2)), 3 weeks on and 1 week off...
July 12, 2017: Oncologist
keyword
keyword
75017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"